SACHI BIOWORKS, INC. — National Aeronautics and Space Administration SBIR Phase III: E014042 SBIR PHASE III RAPID, LOW-COST NANOLIGOMERTM BASED DRUG-DISCOVERY IN SPACE
SACHI BIOWORKS, INC. — SBIR Phase III award from National Aeronautics and Space Administration.
Phase III transition / production-path signal
- Phase III work is typically non-SBIR set-aside follow-on. Seeing SACHI BIOWORKS, INC. at Phase III is a strong transition indicator in this domain.
- Competitors studying dual-use scale-up should treat Phase III firms as graduation benchmarks, not just Phase I/II volume leaders.
- At $5,445,236, this is a large obligation for typical SBIR Phase sizing — worth reviewing for scope breadth and teaming opportunity.
- Tagged technology areas: Space & Satellite, Human Performance & Medical. Follow those hubs for open topics and peer winners in the same cluster.
Summary
Sachi Bioworks received $3.59 million from NASA for a Phase III SBIR project to develop rapid, low-cost drug discovery using nanooligomers in space. The effort advances earlier research toward practical pharmaceutical applications in microgravity.
- Amount
- $5,445,236
- Agency
- National Aeronautics and Space Administration · National Aeronautics and Space Administration
- Program / Phase
- SBIR · Phase III
- NAICS
- 541715 · RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)
- Place of performance
- CO
- Period
- 2023-07-10 → 2028-07-19
Technology domains
Description
E014042 SBIR PHASE III RAPID, LOW-COST NANOLIGOMERTM BASED DRUG-DISCOVERY IN SPACE